PARP-1 inhibitors: Are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?

International Journal of Medical Sciences

Volumn 3, Issue 4, 2006, Pages 117-123

  De Soto, Joseph A ^a   Deng, Chu Xia ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

AG14361; BRCA1; Breast cancer; PARP inhibitors; Therapeutic treatment

Indexed keywords

3 AMINOBENZAMIDE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; AG 14361; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; KU 0051529; KU 0058684; KU 0058948; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; EXPERIMENTAL MODEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; ONCOGENE; REVIEW;

EID: 33749316516     PISSN: 14491907     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.3.117     Document Type: Review

References (54)

1. Garber JE, and Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005; 23: 276-92.
2. Brody LC, and Biesecker BB. Breast cancer susceptibility genes. BRCA1 and BRCA2. Medicine (Baltimore) 1998; 77: 208-26.
3. Ellisen LW, and Haber DA. Hereditary breast cancer. Annu Rev Med 1998; 49: 425-36.
4. Paterson JW. BRCA1: a review of structure and putative functions. Dis Markers 1998; 13: 261-74.
5. Eccles DM, and Pichert G. Familial non-BRCA1/BRCA2-associated breast cancer. Lancet Oncol 2005; 6: 705-11.
6. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684-9.
7. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
8. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108: 171-82.
9. Deng CX. Tumor formation in Brca1 conditional mutant mice. Environ Mol Mutagen 2002; 39: 171-7.
10. Brodie SG, and Deng CX. BRCA1-associated tumorigenesis: what have we learned from knockout mice? Trends Genet 2001; 17: S18-22.
11. Deng CX, and Brodie SG. Roles of BRCA1 and its interacting proteins. Bioessays 2000; 22: 728-37.
12. Deng CX, and Wang RH. Roles of BRCA1 in DNA damage repair: a link between development and cancer. Hum Mol Genet 2003; 12: R113-23.
13. Deng CX. Roles of BRCA1 in centrosome duplication. Oncogene 2002; 21: 6222-7.
14. Zhang J, and Powell SN. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 2005; 3: 531-9.
15. Cantor SB, and Andreassen PR. Assessing the link between BACH1 and BRCA1 in the FA pathway. Cell Cycle 2006; 5: 164-7.
16. Deng CX. Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice. Mutat Res 2001; 477: 183-9.
17. Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response, and cancer evolution. Nucleic Acids Res 2006; 34: 1416-26.
18. Snouwaert JN, Gowen LC, Latour AM, et al. BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of nonhomologous recombination that is corrected by expression of a brca1 transgene. Oncogene 1999; 18: 7900-7.
19. Moynahan ME, Cui TY, and Jasin M. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 2001; 61: 4842-50.
20. Xu X, Aprelikova O, Moens P, et al. Impaired meiotic DNA-damage repair and lack of crossing-over during spermatogenesis in BRCA1 full-length isoform deficient mice. Development 2003; 130: 2001-12.
21. Brodie SG, Xu X, Qiao W, et al. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 2001; 20: 7514-23.
22. Xu X, Weaver Z, Linke SP, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999; 3: 389-95.
23. Kim SS, Cao L, Li C, et al. Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1. Mol Cell Biol 2004; 24: 9498-507.
24. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-7.
25. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
26. Malanga M, and Althaus FR. The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem Cell Biol 2005; 83: 354-64.
27. Dantzer F, Schreiber V, Niedergang C, et al. Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 1999; 81: 69-75.
28. Wong AK, Pero R, Ormonde PA, et al. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 1997; 272: 31941-4.
29. Bryant HE, and Helleday T. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents. Biochem Soc Trans 2004; 32: 959-61.
30. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997; 88: 265-75.
31. Chen J, Silver DP, Walpita D, et al. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells [In Process Citation]. Mol Cell 1998; 2: 317-28.
32. Wang ZQ, Stingl L, Morrison C, et al. PARP is important for genomic stability but dispensable in apoptosis. Genes Dev 1997; 11: 2347-58.
33. Gallmeier E, and Kern SE. Absence of Specific Cell Killing of the BRCA2-Deficient Human Cancer Cell Line CAPAN1 by Poly(ADP-ribose) Polymerase Inhibition. Cancer Biol Ther 2005; 4: 703-6.
34. McCabe N, Lord CJ, Tutt AN, et al. BRCA2-Deficient CAPAN-1 Cells are Extremely Sensitive to the Inhibition of Poly (ADP-Ribose) Polymerase: An Issue of Potency. Cancer Biol Ther 2005; 4: 934-6.
35. Hochegger H, Dejsuphong D, Fukushima T, et al. Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J 2006; 25: 1305-14.
36. De Soto JA, Wang X, Tominaga Y, et al. The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors. Int J Biol Sci 2006; 2: 179-185.
37. Shen SX, Weaver Z, Xu X, et al. A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 1998; 17: 3115-24.
38. Xu X, Wagner KU, Larson D, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation [see comments]. Nat Genet 1999; 22: 37-43.
39. Hanahan D, and Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
40. Xu X, Qiao W, Linke SP, et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 2001; 28: 266-71.
41. Weaver Z, Montagna C, Xu X, et al. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 2002; 21: 5097-107.
42. Cao L, Kim S, Xiao C, et al. ATM-Chk2-p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency. EMBO J 2006; 25: 2167-77.
43. Cao L, Li W, Kim S, et al. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 fulllength isoform. Genes Dev 2003; 17: 201-13.
44. Hakem R, de la Pompa JL, Sirard C, et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 1996; 85: 1009-23.
45. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 [see comments]. Nature 1997; 386: 804-10.
46. Xu X, Li C, Garrett-Beal L, et al. Direct removal in the mouse of a floxed neo gene from a three-loxP conditional knockout allele by two novel approaches. Genesis 2001; 30: 1-6.
47. Hay T, Jenkins H, Sansom OJ, et al. Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy. Cancer Res 2005; 65: 10145-8.
48. Tentori L, and Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005; 52: 25-33.
49. Tentori L, Leonetti C, Scarsella M, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003; 9: 5370-9.
50. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004; 96: 56-67.
51. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003; 2: 371-82.
52. Graziani G, and Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 2005; 52: 109-18.
53. Pacher P, Mabley JG, Soriano FG, et al. Activation of poly(ADPribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging. Int J Mol Med 2002; 9: 659-64.
54. Racz I, Tory K, Gallyas FJr., et al. BGP-15 - a novel poly(ADPribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem Pharmacol 2002; 63: 1099-111.